Drug Type Small molecule drug |
Synonyms BI-732 |
Mechanism EGFR C797S inhibitors(Epidermal Growth Factor Receptor C797S inhibitors), EGFR T790M inhibitors(EGFR T790M inhibitors), EGFR exon 19 deletion inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Preclinical | CN | 18 Apr 2023 | |
EGFR-mutated non-small Cell Lung Cancer | Preclinical | AT | 04 Apr 2023 | |
EGFR-mutated non-small Cell Lung Cancer | Preclinical | KR | 04 Apr 2023 | |
EGFR-mutated non-small Cell Lung Cancer | Preclinical | KR | 04 Apr 2023 |